How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...

The approval is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma.

Among the region’s major 2024 debt deals, BBVA acted as the sole structurer and joint bookrunner on Engen Capital’s approximately $250 million debt issuance. The Spanish bank kicked off 2025 by ...

Recent findings show the upregulation of cell adhesion-related genes on CD34 + cells after daratumumab-based therapy ... R-loop is a nucleic acid structure consisting of a DNA: RNA hybrid and a single ...

In an analysis of the phase III CEPHEUS trial presented at the American Society of Hematology annual meeting, adding daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and ...

Results from a phase 3 clinical trial, published in the New England Journal of Medicine and presented at this week's American Society of Hematology meeting, demonstrated that daratumumab ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

Daratumumab significantly reduced progression risk in smoldering multiple myeloma, especially in high-risk patients, with a 64% reduction compared to active monitoring. The treatment did not ...

Please provide your email address to receive an email when new articles are posted on . Daratumumab delayed progression of smoldering multiple myeloma compared with active monitoring. Among those ...

Phase 3 PERSEUS study of daratumumab subcutaneous (SC) formulation in combination with bortezomib, lenalidomide and dexamethasone induction and consolidation, followed by daratumumab SC and ...